clinical trial · NCT06136598
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
Merck Sharp & Dohme LLC·phase1·completed·n = 14
Prostatic NeoplasmsMetastatic Castration-Resistant Prostate CancerOpevesostatDexamethasoneFludrocortisoneHydrocortisone
brief summary
The primary objectives of this study are to evaluate the safety and tolerability of opevesostat in the treatment of male Chinese participants with metastatic castration-resistant prostate cancer (mCRPC) and to characterize the pharmacokinetic profile of opevesostat. There are no formal hypotheses to be tested in this study.
started
Jan 30, 2024
primary completion
Mar 9, 2026
completion
Mar 9, 2026
last updated
Mar 19, 2026
official title
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol